We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





SARS-CoV-2 Blood Biomarker Identifies Infected Patients Most at Risk of Dying of COVID-19

By LabMedica International staff writers
Posted on 29 Nov 2021

A statistical model developed by researchers uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19. More...

The study by researchers at the Université de Montréal (Montréal, Canada) found that the amount of a SARS-CoV-2 genetic material - viral RNA - in the blood is a reliable indicator in detecting which patients will die of the disease. Despite advances in the management of COVID-19, doctors have found it hard to identify patients most at risk of dying of the disease and so be able to offer them new treatments. Several biomarkers have been identified in other studies, but juggling the profusion of parameters is not possible in a clinical setting and hinders doctors’ ability to make quick medical decisions.

Using blood samples collected from 279 patients during their hospitalization for COVID-19, ranging in degrees of severity from moderate to critical, the research team measured amounts of inflammatory proteins, looking for any that stood out. At the same time, the researchers also measured the amounts of viral RNA and the levels of antibodies targeting the virus. Samples were collected 11 days after the onset of symptoms and patients were monitored for a minimum of 60 days after that. The goal was to test the hypothesis that immunological indicators were associated with increased mortality.

“Among all of the biomarkers we evaluated, we showed that the amount of viral RNA in the blood was directly associated with mortality and provided the best predictive response, once our model was adjusted for the age and sex of the patient,” said Elsa Brunet-Ratnasingham, a doctoral student and co-first author of the study. “We even found that including additional biomarkers did not improve predictive quality.”

“In our study, we were able to determine which biomarkers are predictors of mortality in the 60 days following the onset of symptoms,” said Dr. Daniel Kaufmann, Université de Montréal medical professor who led the research team. “Thanks to our data, we have successfully developed and validated a statistical model based on one blood biomarker,” viral RNA.

Related Links:
Université de Montréal 


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Thyroid Test
Anti-Thyroid EIA Test
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The screening algorithm incorporates two plasma biomarkers: amyloid-beta ratio and p-tau217, which together help indicate brain amyloid burden (Image Credit: Shutterstock)

Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening

Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.